ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Up 34.9% in November

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 39,000 shares, a growth of 34.9% from the November 15th total of 28,900 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 0.0 days.

ZyVersa Therapeutics Stock Down 2.8 %

Shares of ZyVersa Therapeutics stock opened at $1.05 on Friday. The stock’s fifty day moving average is $1.61 and its 200 day moving average is $2.84. ZyVersa Therapeutics has a one year low of $0.98 and a one year high of $25.00.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.